GSK has completed the acquisition of 35Pharma, a Canadian clinical-stage biopharmaceutical company. The key asset is HS235, a molecule targeting the activin receptor signalling pathway — the same pathway as sotatercept — designed for the treatment of pulmonary arterial hypertension.
HS235 is engineered for greater selectivity than existing agents, with the aim of reducing side effects associated with current pulmonary arterial hypertension treatments, notably bleeding, pericardial effusion, and haemoglobin increases.
See also our recent article on this topic here